EBR Systems, Inc. is engaged in the treatment for patients suffering from cardiac rhythm diseases by providing physiological stimulation through endocardiac pacing. The Company is engaged in developing and commercializing Wireless Stimulation Endocardially (WiSE), an implantable, cardiac pacing device able to provide stimulation to endocardial (inside the heart) heart tissue for the correction of heart rhythm conditions without requiring the use of leads. WiSE offers leadless solutions for LV Pacing, including cardiac resynchronization therapy (CRT) and conduction system pacing (CSP). The Company also offers CRT devices through the CRM subsegment under the brand names, including Visionist X4 CRT-P, Valitude X4 (CRT-P), Momentum CRT-D, Resonate X4 CRT-D, and Vigilant X4 CRT-D, among others. The Company operates various subsidiaries, which include EBR Systems (AUST) Pty. Ltd. and EBR Systems (UK) Limited, which establish clinical trials in Australia and the United Kingdom, respectively.

• Revenue in AUD (TTM)0.00
• Net income in AUD-52.64m
• Incorporated2003
• Employees--

• Location
  EBR Systems Inc480 Oakmead ParkwaySUNNYVALE 94085United StatesUSA
• Phone+1 (408) 720-1906
• Fax+1 (408) 720-1996
• Websitehttps://ebrsystemsinc.com/